Abstract
Objective: The primary aim of the study was to determine accuracy, sensitivity and specificity of the Clock Drawing Test (CDT) in detecting probable dementia as compared to the multi-domain dementia screening test DemTect.
Methods: The sample was derived from the general practitioner (GP)-based, cluster-randomized controlled intervention trial DelpHi-MV (Dementia: life- and person-centered help in Mecklenburg-Western Pomerania). Selected from 6.440 patients systematically screened for dementia in primary care, we examined three groups (a,b,c) where the CDT (as index test) as well as the DemTect (as reference standard) were available. After excluding cases with missing values, we included a sample of n=462 with “probable dementia”, n=586 with “mild cognitive impairment” and n=553 with “no cognitive impairment” matched for age and gender. We analyzed the accuracy of the CDT in identifying people with probable dementia by the DemTect and report sensitivity, and specificity for the CDT. We further analyzed age and gender differences associated with the groups.
Results: In comparison to the DemTect the CDT identified more than twice as many of the screened patients as cognitively impaired (63.1% in the CDT vs. 28.9% in the DemTect). The sensitivity and specificity for the CDT were 84.4% and 45.6% respectively. We found considerable age and gender differences for the performance of the CDT. Higher age (p < 0.001) and female sex (p < 0.001) were associated with incorrect clock drawings.
Conclusion: The CDT shows a considerably high rate of false positive screening outcomes compared to the DemTect and disadvantages older people and women. Thus, in contrary to previous findings our results indicate that the CDT should not be used as exclusive instrument to screen for probable dementia in primary care.
Keywords: Clock drawing test, probable dementia, screening instrument, primary care, DelpHi-MV, DemTect.
Current Alzheimer Research
Title:The Clock Drawing Test: A Reasonable Instrument to Assess Probable Dementia in Primary Care?
Volume: 15 Issue: 1
Author(s): Katinka Reiner, Tilly Eichler, Johannes Hertel, Wolfgang Hoffmann and Jochen Rene Thyrian*
Affiliation:
- German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Greifswald,Germany
Keywords: Clock drawing test, probable dementia, screening instrument, primary care, DelpHi-MV, DemTect.
Abstract: Objective: The primary aim of the study was to determine accuracy, sensitivity and specificity of the Clock Drawing Test (CDT) in detecting probable dementia as compared to the multi-domain dementia screening test DemTect.
Methods: The sample was derived from the general practitioner (GP)-based, cluster-randomized controlled intervention trial DelpHi-MV (Dementia: life- and person-centered help in Mecklenburg-Western Pomerania). Selected from 6.440 patients systematically screened for dementia in primary care, we examined three groups (a,b,c) where the CDT (as index test) as well as the DemTect (as reference standard) were available. After excluding cases with missing values, we included a sample of n=462 with “probable dementia”, n=586 with “mild cognitive impairment” and n=553 with “no cognitive impairment” matched for age and gender. We analyzed the accuracy of the CDT in identifying people with probable dementia by the DemTect and report sensitivity, and specificity for the CDT. We further analyzed age and gender differences associated with the groups.
Results: In comparison to the DemTect the CDT identified more than twice as many of the screened patients as cognitively impaired (63.1% in the CDT vs. 28.9% in the DemTect). The sensitivity and specificity for the CDT were 84.4% and 45.6% respectively. We found considerable age and gender differences for the performance of the CDT. Higher age (p < 0.001) and female sex (p < 0.001) were associated with incorrect clock drawings.
Conclusion: The CDT shows a considerably high rate of false positive screening outcomes compared to the DemTect and disadvantages older people and women. Thus, in contrary to previous findings our results indicate that the CDT should not be used as exclusive instrument to screen for probable dementia in primary care.
Export Options
About this article
Cite this article as:
Reiner Katinka , Eichler Tilly, Hertel Johannes , Hoffmann Wolfgang and Thyrian Rene Jochen *, The Clock Drawing Test: A Reasonable Instrument to Assess Probable Dementia in Primary Care?, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170908101822
DOI https://dx.doi.org/10.2174/1567205014666170908101822 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives
Current Computer-Aided Drug Design Lipoic Acid Metabolism of Plasmodium - A Suitable Drug Target
Current Pharmaceutical Design Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Macrophage Colony-Stimulating Factor (M-CSF) in Plasma and CSF of Patients with Mild Cognitive Impairment and Alzheimers Disease
Current Alzheimer Research A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews Focusing on New Monoamine Oxidase Inhibitors: Differently Substituted Coumarins As An Interesting Scaffold
Current Topics in Medicinal Chemistry Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms
Current Medicinal Chemistry Antiphospholipid Syndrome: Characteristics and Obstetrical Management
Current Drug Targets HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Current Medicinal Chemistry Molecular Mechanisms, Emerging Etiological Insights and Models to Test Potential Therapeutic Interventions in Alzheimers Disease
Current Alzheimer Research Estrogen Receptors: Mechanism of Action and Relevance to Schizophrenia
Current Psychiatry Reviews Arundic Acid (ONO-2506) Ameliorates Delayed Ischemic Brain Damage by Preventing Astrocytic Overproduction of S100B
Current Drug Targets - CNS & Neurological Disorders Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued)